BBSW 2020 Oct Meetup on Career Development

By the Bay Area Biotech-pharma Statistics Workshop (BBSW)

2020/10/22 (4:00-5:30pm PST), Zoom

Challenges and Opportunities in Small-to-midsize Pharma vs. Large Pharma

- Statistician roles
- Advocating value of statistics/biometrics
- Networking
- Building vision/infrastructure
- Vendor selection

Discussion Leads

Chris Cabanski

- Director of Biostatistics, Parker Institute for Cancer Immunotherapy

Natasa Rajicic

- Executive Director of Biometrics, Arrowhead pharma

Rick Landin

- President & CEO, Presagia

Moderator



Julia Varshavsky

- Founder and Managing Director, OccamPoint

LIMITED SEATS - REGISTRATION REQUIRED!

https://bbsw-tickets.ticketleap.com/2020oct/

BBSW 2020 Oct Meetup on Career Development

By the Bay Area Biotech-pharma Statistics Workshop (BBSW)

Chris Cabanski, PhD, is the Director of Biostatistics at PICI. His group is responsible for biostatistics, statistical programming and clinical reporting deliverables for all PICI-sponsored clinical trials. His career interests include early stage (Phase I and II) clinical trial design, data visualization and biomarker analysis.Chris previously worked as a senior biostatistician at Genentech, where he helped develop several early stage molecules across various immunological diseases including asthma and idiopathic pulmonary fibrosis. Chris received his PhD in statistics and operations research from the University of North Carolina at Chapel Hill.

Natasa Rajicic, ScD, has recently started at Arrowhead Pharmaceuticals as an Executive Director of Biometrics. Prior to Arrowhead, Natasa spent three years at Cytel as a Principal of Strategic Consulting, helping clients apply appropriate study designs and answer difficult problems in clinical development. Natasa was also a Director in biostatistics at Pfizer Inc in New York for over 10 years where she worked on several late-stage development projects in different therapeutic areas. Prior to joining Pfizer, Natasa learned about clinical trials at the Center for Biostatistics in AIDS Research at Harvard School of Public Health in Boston as a statistician on Phase 2-4 HIV/AIDS clinical trials. Natasa received a bachelor's degree in mathematics and a master's degree in statistics from West Virginia University, and a doctorate degree in biostatistics from Harvard T.H. Chan School of Public Health. She currently holds a lecturer position at Columbia University School of Professional Studies.

Rick Landin, PhD, has over 25 years of drug development experience ranging from preclinical to post-commercialization. His therapeutic areas of expertise include precision medicine, oncology, asthma and allergy, migraine, insomnia, depression, general anxiety disorder, multiple sclerosis, lupus, and rheumatoid arthritis. During his time in the industry, Dr. Landin has established a history of building, managing and leading Biometrics organizations in large R&D (Marion Merrell Dow, Eli Lilly, Biogen), small-to-midsize-pharma (IDEC, Neurocrine), as well as pre-commercialization (Ambit, Ignyta, La Jolla Pharmaceuticals). In addition, he has served and led cross functional, multi-corporate teams, leading to regulatory submission and approval of multiple products. Dr. Landin holds a Ph.D. is Statistics from Texas A&M University. Since graduating from Texas A&M, Dr. Landin has been committed to the practical application of statistical theory for the advancement of drug development, with successes including the following: development of the Theory of Selective Score Inflation to redesign depression studies, the creation of innovative endpoints for the measure of Sleep Maintenance, innovative data presentation of QTc data, and most recently serving as a catalyst in the development of a precision medicine toolbox based on advances in applied math/machine learning.

Julia Varshavsky, PhD, has over 15 years of drug development experience spanning areas from drug discovery through commercialization and life-cycle management. Her therapeutic area expertise includes orphan and non-orphan indications across therapeutic areas encompassing endocrinology, asthma, allergy, immunology, critical care, oncology, CNS and sleep and movement disorders. During her tenure in the industry, Dr. Varshavsky served in a variety of leadership roles in both large R&D (Eli Lilly, Genentech) and small-to-midsize pharma (Jazz Pharmaceuticals, Corcept Therapeutics) organizations, building and leading Biostatistical, Biometrics and Development teams towards key deliverables such as global BLAs and NDAs, development and life cycle plans, and business opportunity assessments. As a member of corporate leadership teams, Dr. Varshavsky conducted benefit-risk assessments of clinical programs to enable positive and negative portfolio decisions. She represented sponsors at Data Monitoring Committees, Advisory Boards, patient advocacy groups, and NIH. In 2019 Dr. Varshavsky founded OccamPoint, a consortium of drug and combination product development professionals, to aid assessment of investment risk in healthcare and digital health products during due diligence and business development. Consortium members also serve as coaches, guides and technical experts to startup founders helping with the formation of the product development strategies, entry into the marketplace, and supporting access to funding. As a Life Sciences Council member for Springboard Enterprises, Dr. Varshavsky works with peers in finance, legal and investment communities to foster success of female-led healthcare and digital health startups, coaching on a broad range of topics including indication-specific product development, use of AI in patient selection and diagnostics, as well as scalable and efficient data aggregation and sharing strategies. As a member of investment groups, Dr. Varshavsky conducts due diligence to help guide investment decisions in transformative healthcare technologies and medicines. Dr. Varshavsky holds a Ph.D. in Statistics from Purdue University. She has published and presented on theoretical and applied aspects of Bayesian statistics, clinical trial design and analysis, and drug development process optimization.